Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$2.60
-4.4%
$3.03
$2.30
$5.54
$162.88M-0.17276,068 shs644,810 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.07
-3.7%
$12.61
$5.22
$27.38
$157.73M0.43146,569 shs132,390 shs
MediWound Ltd. stock logo
MDWD
MediWound
$18.99
-0.5%
$19.36
$13.49
$24.00
$206.32M0.3890,992 shs74,898 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.32
+1.5%
$1.10
$0.51
$2.45
$59.11M0.8300,085 shs135,475 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
0.00%-5.23%-10.82%-24.65%-0.37%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+0.80%-1.03%-19.47%+85.36%
MediWound Ltd. stock logo
MDWD
MediWound
0.00%-6.51%-6.28%+16.05%+41.83%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.00%-9.09%+17.12%-7.14%+85.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.7526 of 5 stars
3.54.00.00.02.81.70.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.9664 of 5 stars
3.50.01.72.72.61.71.3
MediWound Ltd. stock logo
MDWD
MediWound
1.5891 of 5 stars
3.51.00.00.00.00.80.6
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.2532 of 5 stars
3.65.00.00.02.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
3.00
Buy$9.00246.15% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50152.69% Upside
MediWound Ltd. stock logo
MDWD
MediWound
3.00
Buy$31.8067.46% Upside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.29
Buy$8.00506.06% Upside

Current Analyst Ratings Breakdown

Latest QNCX, MDWD, LFVN, and ELDN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$9.00
6/13/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/4/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$34.00
5/22/2025
MediWound Ltd. stock logo
MDWD
MediWound
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00 ➝ $31.00
5/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
3/25/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $4.00
3/24/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.98 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.76$0.85 per share14.21$2.05 per share5.89
MediWound Ltd. stock logo
MDWD
MediWound
$20.22M10.15N/AN/A$2.89 per share6.57
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A$0.69 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6917.49N/A4.12%34.67%15.24%8/27/2025 (Estimated)
MediWound Ltd. stock logo
MDWD
MediWound
-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/13/2025 (Estimated)
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$56.83M-$1.39N/AN/AN/AN/A-117.52%-34.22%8/12/2025 (Estimated)

Latest QNCX, MDWD, LFVN, and ELDN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million
5/14/2025Q1 2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.28-$0.08+$0.20-$0.08N/AN/A
5/13/2025Q1 2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.24-$0.34-$0.10-$0.34N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/24/2025Q4 2024
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.19-$0.28-$0.09-$0.28N/A$0.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.49%N/A26.09%3 Years
MediWound Ltd. stock logo
MDWD
MediWound
N/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A

Latest QNCX, MDWD, LFVN, and ELDN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
13.90
13.91
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
MediWound Ltd. stock logo
MDWD
MediWound
N/A
2.15
1.99
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.82
4.05
4.05

Institutional Ownership

CompanyInstitutional Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
MediWound Ltd. stock logo
MDWD
MediWound
46.83%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%

Insider Ownership

CompanyInsider Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
12.30%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
MediWound Ltd. stock logo
MDWD
MediWound
9.20%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
16.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1059.88 million52.52 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
MediWound Ltd. stock logo
MDWD
MediWound
8010.81 million9.81 millionOptionable
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6045.47 million37.83 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$2.60 -0.12 (-4.41%)
Closing price 04:00 PM Eastern
Extended Trading
$2.79 +0.19 (+7.27%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.07 -0.46 (-3.67%)
Closing price 04:00 PM Eastern
Extended Trading
$12.10 +0.03 (+0.25%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MediWound stock logo

MediWound NASDAQ:MDWD

$18.99 -0.10 (-0.52%)
Closing price 04:00 PM Eastern
Extended Trading
$20.01 +1.02 (+5.37%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$1.32 +0.02 (+1.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 -0.07 (-4.92%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.